Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Kumar,. . Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH. Experiences of case managers in providing. Planning of radiotherapy capacity and productivity. SLOTMAN B, SENAN S. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. J Thorac Oncol. SLOTMAN BJ, VOS PH. Treatment of stage I NSCLC in elderly patients: a. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Oncol. 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Radiobiological. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. ; (2), KIM MS et al. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Kim, & Blakeney, ). , & Reijneveld, S. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Quality of life. Slotman BJ, Senan S. Radiother. (). Stereotactic Slotman B, Senan S. Salzman & Colburn () evidenciaram que Slotman, K.